8 results
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
) Clinical Manifestations ... autoantibodies that will cause ... thrombosis and/or blood-brain ... #rheumatology # ... cerebritis #diagnosis #management
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
40, F:M 9:1 • Clinical ... Manifestations: Malar rash ... Positive in 60-80% of cases ... life-threatening • Treatment ... #Summary #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... 40, F:M 9:1 • Clinical ... comparison #table #rheumatology ... #diagnosis #management
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
Phagocytosis of blood ... Autoimmune diseases: SLE ... Drugs, Unknown cause ... Lymphohistiocytosis #diagnosis #management ... #rheumatology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
nervous system (CNS ... Petechial or purpuric rash ... erythematosus [SLE ... Treatment: • Corticosteroids ... Syndrome #Diagnosis #Management
Disseminated Intravascular Coagulation (DIC) Overview

Increased Clotting and Consumption of Clotting Factors

Findings:
 • Bleeding
 • Recent history
ABO incompatible blood ... organ damage Clinical ... Thromboembolism (7%) • CNS ... #treatment #management ... #hematology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
overlaps with RA, SLE ... salivary ducts Clinical ... Adenocarcinoma Treatment ... Sjogrens #Syndrome #Rheumatology ... #Diagnosis #Management
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... Discontinuation of causal ... DrugInduced #Lupus #DIL #rheumatology ... #management